Journal article
DNA therapy for asthma
Current opinion in allergy and clinical immunology, Vol.2(1), pp.69-73
02/2002
DOI: 10.1097/00130832-200202000-00011
PMID: 11964753
Abstract
Asthma therapy, like other therapies, has been moving towards a molecular basis for several years. This year, there have been several preclinical studies published which utilize attributes or facets of DNA to address asthma therapeutics. These include antisense oligonucleotides (against the nuclear transcription factor GATA-3 and the mast cell chemotactic agent, stem cell factor), gene transfer (of interleukin-18, both by plasmid and viral vectors), and CpG oligodeoxynucleotides (which suppress Th2 and stimulate Th1 responses). No clinical experience has yet been reported for any of these areas of research in asthma, but clinical trials are ongoing utilizing CpG oligonucleotides.
Details
- Title: Subtitle
- DNA therapy for asthma
- Creators
- Joel N Kline - Department of Medicine, University of Iowa, 200 Newton Road, Iowa City, IA 52242, USA. joel-kline@uiowa.edu
- Resource Type
- Journal article
- Publication Details
- Current opinion in allergy and clinical immunology, Vol.2(1), pp.69-73
- DOI
- 10.1097/00130832-200202000-00011
- PMID
- 11964753
- ISSN
- 1528-4050
- eISSN
- 1473-6322
- Language
- English
- Date published
- 02/2002
- Academic Unit
- Pulmonary, Critical Care, and Occupational Medicine; Occupational and Environmental Health; Internal Medicine
- Record Identifier
- 9984094619402771
Metrics
36 Record Views